Presenilin-1 polymorphism in patients with Alzheimer's disease, vascular dementia and alcohol-associated dementia in Japanese population

Acta Neurologica Scandinavica

Volumn 94, Issue 5, 1996, Pages 326-328

  Isoe, K ^a   Urakami, K ^a   Ji, Y ^a   Adachi, Y ^a   Nakashima, K ^a  

^a TOTTORI UNIVERSITY   (Japan)

Author keywords

Genetics; Prevalence; Risk factor

Indexed keywords

ALCOHOL; PRESENILIN; PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DRUG ABUSE; FEMALE; GENETIC POLYMORPHISM; HUMAN; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIINFARCT DEMENTIA;

EID: 0029821568     PISSN: 00016314     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0404.1996.tb07074.x     Document Type: Article

References (16)

1. SHERRINGTON R, ROGAEV EI, LIANG Y, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 1995: 375: 754-60.
2. WRAGG M, HUTTON M, TALBOT C, and the Alzheimer's disease Collaborative Group. Genetic association between intronic polymorphism in presenilin-1 gene and late-onset Alzheimer's disease. Lancet 1996: 347: 509-12.
3. KEHOE P, WILLIAMS J, LOVESTONE S. Presenilin-1 polymorphism and Alzheimer's disease. Lancet 1996: 347: 1185.
4. HIGUCHI S, MURAMATSU T, MATSUBARA S, ARAI H, SASAKI H. Presenilin-1 polymorphism and Alzheimer's disease. Lancet 1996: 347: 1186.
5. SCOTT WK, GROWDON JH, ROSES AD, HAINES JL, PERICAK-VANCE MA. Presenilin-1 polymorphism and Alzheimer's disease. Lancet 1996: 347: 1186-7.
6. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition. Washington, D.C.: American Psychiatric Association. 1994.
7. MCKHAAN G, DRACHMAN D, FOLSTEIN M, KATZMAN R, PRICE D, STADLAN EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984: 34: 934-44.
8. CHUI HC, VICTOROFF JI, MARGOLIN D, JAGUST W, SHANKLE R, KATZMAN R. Criteria for the diagnosis of ischemic vascular dementia proposed by the State of California Alzheimer's Disease Diagnostic and Treatment Centers. Neurology 1992: 42: 473-80.
9. WENHAM PR, PRICE WH, BLUNDELL G. Apolipoprotein E genotyping by one-stage PCR. Lancet 1991: 337: 1158-9.
10. CORDER EH, SAUNDERS AM, STRITTMATTER WJ et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993: 261: 921-3
11. TALBOT C, LENDON C, CRADDOCK N, SHEARS S, MORRIS JC, GOATE A. Protection against Alzheimer's disease with apoE ε 2. Lancet 1994: 343: 1432-1433.
12. BENJAMIN R, LEAKE A, MCARTHUR FK, et al. Protective effect of apoE ε 2 in Alzheimer's disease. Lancet 1994: 344: 473.
13. ISOE K, URAKAMI K, SATO K, TAKAHASH K. Apolipoprotein E in patients with dementia of the Alzheimer type and vascular dementia. Acta Neurol Scand 1996: 93: 133-7.
14. KAMBOH MI, SANGHER DK, FERREEL R, DEKOSKY S. APOE 4-associated Alzheimer's disease risk is modified by α1-antichymotrypsin polymorphism. Nature Genet 1995: 10: 486-8.
15. SAKODA S, KURIYAMA M, OSAME M, et al. Apolipoprotein E ε 4. Neurology 1994: 44: 2420.
16. FRISONI GB, BIANCHETTI A, GOVONI S, TRABUCCHI M, CALABRESI L, FRANCESCHINI G. Association of apolipoprotein E E4 with vascular dementia. JAMA 1994: 271: 1317